home / stock / adap / adap quote
Last: | $1.02 |
---|---|
Change Percent: | 0.0% |
Open: | $1.06 |
Close: | $1.02 |
High: | $1.06 |
Low: | $1 |
Volume: | 740,677 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.02 | $1.06 | $1.02 | $1.06 | $1 | 740,677 | 07-04-2024 |
$1.02 | $1.06 | $1.02 | $1.06 | $1 | 740,677 | 07-03-2024 |
$1.05 | $1.07 | $1.05 | $1.1 | $1.03 | 1,611,906 | 07-02-2024 |
$1.05 | $1 | $1.05 | $1.06 | $0.9799 | 1,432,744 | 07-01-2024 |
$0.9749 | $0.9808 | $0.9749 | $1.03 | $0.9601 | 1,600,236 | 06-28-2024 |
$0.9808 | $0.84 | $0.9808 | $0.9896 | $0.83 | 2,723,951 | 06-27-2024 |
$0.8315 | $0.865 | $0.8315 | $0.865 | $0.825 | 1,715,298 | 06-26-2024 |
$0.8659 | $0.8909 | $0.8659 | $0.8909 | $0.86265 | 774,847 | 06-25-2024 |
$0.8806 | $0.89 | $0.8806 | $0.919 | $0.875 | 755,062 | 06-24-2024 |
$0.89 | $0.865 | $0.89 | $0.896392 | $0.8641 | 588,973 | 06-21-2024 |
$0.8728 | $0.87 | $0.8728 | $0.9 | $0.855 | 1,862,992 | 06-20-2024 |
$0.88 | $0.93 | $0.88 | $0.9401 | $0.85 | 2,798,180 | 06-19-2024 |
$0.88 | $0.93 | $0.88 | $0.9401 | $0.85 | 2,798,180 | 06-18-2024 |
$0.937 | $1.01 | $0.937 | $1.02 | $0.9212 | 1,992,746 | 06-17-2024 |
$1.01 | $1.02 | $1.01 | $1.0399 | $1 | 834,358 | 06-14-2024 |
$1.04 | $1.05 | $1.04 | $1.05 | $1.02 | 599,829 | 06-13-2024 |
$1.04 | $1.05 | $1.04 | $1.08 | $1.03 | 882,889 | 06-12-2024 |
$1.04 | $1.02 | $1.04 | $1.05 | $1.01 | 1,642,351 | 06-11-2024 |
$1.04 | $1.01 | $1.04 | $1.045 | $1.01 | 1,624,762 | 06-10-2024 |
$1.02 | $1.01 | $1.02 | $1.06 | $1.01 | 1,076,531 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...